
|Videos|January 22, 2019
Perioperative Immunotherapy the Future of HCC Treatment?
Author(s)Ahmed Kaseb, MD
Cancer Network spoke with Dr. Ahmed Kaseb about a phase II pilot trial of perioperative immunotherapy for resectable HCC and how the results could change future perioperative treatment of the disease.
Advertisement
Cancer Network spoke with Dr. Ahmed Kaseb about a phase II pilot trial of perioperative immunotherapy for resectable HCC and how the results could change future perioperative treatment of the disease.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer
2
Novel Agent Earns FDA Breakthrough Therapy Designation for HPV+ Oropharyngeal Cancer
3
Debating Camizestrant, ctDNA Monitoring, and SERENA-6 in HR+ Breast Cancer
4
Saturated Fat Intake Linked to Greater Mortality in Nonmetastatic Prostate Cancer
5
















































